PHASE III--PLATINUM COMPOUND AND PACLITAXEL IN EPITHELIAL OVARIAN CARCINOMA

卵巢癌患者的生存率相对 在过去的20年里一直如此。直到最近，环磷酰胺和顺铂 被认为是晚期上皮细胞癌患者的标准治疗 卵巢癌然而，根据GOG研究，紫杉醇和顺铂 已经成为新的标准疗法另一项GOG研究（试点）， 显示紫杉醇和卡铂的组合是一种活性药物， 方案，毒性是可接受的，化疗耐受性良好， 患者目前的研究将解决输注时间的问题， 紫杉醇。

Survival for patients with ovarian cancer has remained relatively constant for the last 20 years. Until recently, Cytoxan and cisplatin was considered to be standard therapy for patients with advanced epithelial ovarian cancer. However, based on a GOG study, paclitaxel and cisplatin has become the new standard regimen. Another GOG study (a pilot), revealed that the combination of paclitaxel and carboplatin was an active regimen, toxicity was acceptable and the chemo was well tolerated by patients. This current study will address the issue of infusion time for paclitaxel.